Multiple sclerosis (MS) has a substantial negative impact on health-related quality of life. Clinical assessments often do not include standardised, routine assessment of MS impact from the patient perspective, and communication between healthcare practitioners (HCPs) and patients can be lacking. Thus, there is a need for patient-reported outcome (PRO) measures to encourage patient-HCP communication, to help inform HCPs of matters important to patients and to aid both patients and HCPs in managing the disease.
diseases. [5] [6] [7] Compounding the negative impact of MS on HRQoL are the challenges faced by MS specialists, neurologists and general healthcare practitioners (HCPs) in managing patients with MS owing to high patient heterogeneity in terms of disease severity, comorbidities, symptoms, the impact of symptoms on HRQoL and the transient nature of symptoms.
Often, standard clinical assessments do not provide enough information for HCPs to effectively manage the disease and improve HRQoL. 
Patient-Based Assessment
The Institute of Medicine of the US National Academy of Sciences names patient-centred care as one of six domains of healthcare quality. 9 In patient-centred care, the patient's perspective on her/ his condition is valued, and information regarding the patient's experience is considered in clinical care and treatment decisionmaking. The UK National Institute for Health and Care Excellence (NICE) recommends patient participation in all aspects of MS healthcare as well as self-management of general health. 10 As the experience of MS varies greatly from person to person and because some treatment effects can only be identified by the individual patient, the routine assessment of disease severity and outcomes from the patient perspective is especially important for comprehensive health assessment and clinical decision-making. Enhancing HCP-patient participatory decision-making may improve patient adherence, health outcomes and satisfaction in MS. [11] [12] [13] [14] DOI: 10.17925/ENR.2014.09.01.49 Patient-reported outcome (PRO) instruments facilitate patient-centred care and can encourage communication between patients and physicians. [15] [16] [17] [18] Compared with standard clinical testing, PRO instruments more fully reflect the patient's experience of life with diseases such as MS, the patient's perception of the effects of treatment and the disease course, thereby providing a quantifiable and broader measure of the impact of disease. For example, at the clinical appointment, the patient may be asked generally, 'How are you?' Although it can be used to ask patients to reflect on their status, this type of question does not provide direction regarding specific symptoms or HRQoL aspects that may help inform disease status or how to proceed with management. 19 In addition, PRO measures for MS contribute unique information that is not captured via the most commonly used measures of clinical disease severity (e.g., Expanded Disability Status Scale [EDSS] , magnetic resonance imaging and relapse rate).
Additional benefits of routine PRO assessment include providing a baseline from which to tailor treatments and assess their effectiveness, screening for hidden problems and facilitating the detection of aspects of the condition that would otherwise go unrecognised (e.g., serve as an early indicator regarding the changing impact of the condition and signal the need for additional follow-up). PROs also help patients and HCPs monitor changes and responses to treatment that are meaningful to the patient. 20 Routine PRO assessment can also improve patient-HCP communication and patient self-management of their disease, both aspects potentially resulting in improved outcomes. Through routine self-monitoring, patients are more likely to become active in disease management and treatment decision-making, which in turn may lead to improved treatment compliance, and ultimately, improved outcomes. 17, 18, 21 Furthermore, by providing patients with reference material to discuss with their HCP, PRO instruments open lines of communication between patient and HCP, enhancing rapport and interpersonal relationships. 15, 16, 18, [22] [23] [24] A study evaluating the relationship between HCP-patient communication and patient adherence found a 19 % higher risk of non-adherence to treatment when the patient's HCP is poor at communicating compared with HCPs who communicate well. 25 Thus, increasing HCP-patient communication around the full impact of disease and treatment may lead to increased treatment compliance, which in turn can result in improved patient outcomes.
To facilitate participation in patient-centred care, researchers and clinicians are becoming increasingly dependent on technological advances for PRO assessment, including web-based interventions and mobile phone applications. Recent studies have shown that these modalities are effective for health screening, education and intervention, and can even improve health outcomes. [26] [27] [28] [29] Studies in MS in particular have shown that patients are not only willing to utilise technology to report on their health, but that these methods are successful at obtaining valuable patient-level information. [30] [31] [32] A recent study evaluated Internet use in 586 MS patients and found that 94 % had Internet access, with approximately one-third seeking MS-specific information. 31 In the same study, nearly 68 % of MS patients accepted communication with their HCP via mobile phone, Internet or email. Because technology and its use will continue to advance, integrating web-based interventions in MS patient care will ultimately help improve patient outcomes.
Challenges in Assessing Health-related Quality of Life and Outcomes in Daily Practice
Despite the benefits of PRO instruments in improving HRQoL and overall patient outcomes, several obstacles exist that prevent their use in daily practice. Although PRO measures are often well accepted by patients, 18, 22 conflicting evidence exists regarding HCP perceptions of the usefulness of these instruments. 14, 33 Barriers to the use of PRO data by HCPs may be practical (e.g., lack of financial or personnel resources for administration, scoring, collection, storage and retrieval of data; perceived time burden for HCPs and patients), 14, 34, 35 methodological (e.g., how to effectively and efficiently use the information) 33, 34, 36 or cultural. 14 Challenges related to the utility of PRO instruments in particular include a lack of normative data for MS patients, 37 lack of interpretation guidelines for changes in individual patients over time, 34, 38 instruments focused on a single symptom (e.g., pain, fatigue) and a wide proliferation of instruments, thus causing confusion regarding which instrument best characterises HRQoL, especially in MS. 14 It is crucial for HCPs to seek regular input from patients with regard to the experience of the disease and how it affects HRQoL in order to maximise patient outcomes. 2, 17, 39 Not only are HCPs faced with challenges in terms of incorporating PROs in clinical practice, but there have been studies suggesting a lack of effective communication between HCPs and their patients with regard to factors affecting HRQoL as well as which aspects of HRQoL are most relevant. 40, 41 Therefore, there is a need to empower MS HCPs with better communication and decisionmaking skills and to improve attention to MS patient preferences for reception of information and involvement in health decisions. 42 Taking all of these factors into consideration, the present challenge is to identify a 'tool set' that meets the following criteria: 
MSdialog Background
Given the substantial disease burden and the current lack of tools to support effective and efficient patient-provider communication, a practical approach to the routine assessment of outcomes data from patients with MS is warranted.
In recent years, health information technology innovations have emerged, including electronic systems for data capture, information management, remote monitoring and management, health record integration and reporting, to close quality gaps in disease management and to help patients to achieve optimal health outcomes. 4, [43] [44] [45] [46] Electronic data capture and reporting systems enable the routine, remote collection of data from patients in a timely, user-friendly and often cost- Initial PRO concepts to be included in MSdialog were identified through a multi-year strategic planning process that involved several structured workshops with international representation, prototype software demonstrations and input from major stakeholders via a multi-country qualitative marketing research study. This study was conducted with MS patients (n=24), clinic nurses (n=14) and neurologists (n=15) from Sweden, the UK and Canada. Participants were provided with a demonstration of the MSdialog application, and interviewers gathered feedback on the overall application and its individual features. HCPs (neurologists and nurses) reported that the application could provide useful information on patient outcomes to prepare for an appointment and/or streamline discussions with the patient at the time of a clinic visit. They also reported that MSdialog information could help to engage patients in the 'ownership' and management of their condition and could be useful Results from this research helped to identify initial PRO concepts to be included in MSdialog and informed further development of features in the MSdialog application.
Understanding of Novel Patient-reported Outcome 'Territory'
The US Food and Drug Administration (FDA) PRO Guidance, 47 European Medicines Agency (EMA) HRQoL Reflection Paper, 48 
Instrument Evaluation and Selection
The selection of these initial PRO measures resulted from extensive literature review, instrument evaluation and recommendations from specialists in the development, testing and application of PROs. important health concepts for patients with MS (in this case, the focus was on relapsing-remitting MS). 4 The results identified the following symptom concepts as most important and relevant to patients: pain, musculoskeletal symptoms (i.e., muscle stiffness, limb tremor/spasm, weakness in limbs), bladder and bowel concerns, fatigue, visual impairment and altered sensations (e.g., feelings of numbness). The following impact concepts were identified as important and relevant to patients: physical function, activities of daily living (ADL), emotional function, social function, cognitive function, sleep quality, sexual function, treatment satisfaction, patient satisfaction and overall QoL (see Figure   1 ). Results from this literature review informed PRO concept selection for MSdialog, although final decisions regarding concept coverage were also based on feedback from interviews and discussions with patients, physicians, nurses through the qualitative marketing study, content area experts and Merck Serono internal expert functions.
Next, an instrument evaluation was conducted to determine whether any existing measures covered the measurement concepts of key interest to Merck Serono for the initial launch of MSdialog. The instrument evaluation started with a focus on existing condition-specific instruments, since they generally are more sensitive than generic measures. Because PRO data are visualised in a single customisable graphical display for patients, steps were taken to ensure that the MusiQoL and MSLQI scores are presented on the same metric, scored in the same direction. Raw scores were linearly transformed to a 0 to 100 metric, with higher scores representing better health (see Figure 3 for a sample display of scores). Item-level scores for all completed instruments are available to the HCP for review. While this development effort followed a systematic process for selection of PRO instruments for MSdialog, it also identified a need for further validation work on a few of the scales in the MSQLI. For example, there are some scales with demonstrated reliability and validity, but lacking evidence of responsiveness (sensitivity to changes in the clinical condition over time). A validation study to evaluate instrument measurement properties can address these gaps. In addition, since both the MusiQoL and MSQLI use a 4-week recall period, a validation study can evaluate instrument versions using a 1-week recall period, which may enable additional options to the user for more frequent HRQoL monitoring.
Instrument Implementation in MSdialog
Several steps were taken in order to implement the PRO instruments in MSdialog. First, applicable instrument licenses and permission to use were secured. Planned use, number of administrations, duration of data collection activity and number of translations are some of the things that need to be considered when approaching this discussion with an author/distributor.
Since the MusiQoL and MSQLI instruments were originally developed and validated in paper version, we evaluated the potential for a successful migration of these instruments to electronic administration (in this Table 1 ).
Finally, a user guide was developed for HCPs to provide an overview of MSdialog with a specific focus on the MusiQoL and MSQLI instruments. The guide describes each instrument and its scoring procedures, and provides preliminary guidelines for interpretation. It is intended to support clinician and patient use of these PRO instruments on MSdialog.
Future Plans
Future plans involve launch of MSdialog outside Europe, which will require additional translation and linguistic validation efforts for each new country/language translation. Because normative interpretation guidelines are generally lacking for PRO instruments that are commonly used with patients who have MS, 54 additional research can support more extensive guidelines for the interpretation of PRO data. 
Conclusion

